Eagle Pharmaceuticals (NASDAQ:EGRX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note released on Monday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

EGRX stock opened at $4.61 on Monday. Eagle Pharmaceuticals has a 1-year low of $3.21 and a 1-year high of $18.10. The business has a 50-day moving average price of $5.08 and a 200 day moving average price of $4.90. The company has a market capitalization of $59.87 million, a P/E ratio of 3.91 and a beta of 0.51.

Hedge Funds Weigh In On Eagle Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Los Angeles Capital Management LLC boosted its position in Eagle Pharmaceuticals by 68.1% during the 4th quarter. Los Angeles Capital Management LLC now owns 91,262 shares of the specialty pharmaceutical company’s stock valued at $477,000 after acquiring an additional 36,982 shares in the last quarter. BNP Paribas Financial Markets boosted its position in Eagle Pharmaceuticals by 378.7% during the fourth quarter. BNP Paribas Financial Markets now owns 88,685 shares of the specialty pharmaceutical company’s stock valued at $464,000 after purchasing an additional 70,158 shares in the last quarter. Jump Financial LLC grew its stake in Eagle Pharmaceuticals by 172.0% in the fourth quarter. Jump Financial LLC now owns 38,900 shares of the specialty pharmaceutical company’s stock valued at $203,000 after purchasing an additional 24,600 shares during the last quarter. Trexquant Investment LP raised its holdings in Eagle Pharmaceuticals by 88.0% in the fourth quarter. Trexquant Investment LP now owns 126,282 shares of the specialty pharmaceutical company’s stock worth $660,000 after purchasing an additional 59,095 shares in the last quarter. Finally, Oxford Asset Management LLP purchased a new stake in shares of Eagle Pharmaceuticals during the fourth quarter valued at about $101,000. 85.36% of the stock is currently owned by institutional investors.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.